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ABSTRACT 
SEROPREVALENCE OF HEPATITIS B SURFACE ANTIGEN AND ANTIBODIES TO 
HEPATITIS C IN PATIENTS ATTENDING TERTIARY CARE HOSPITAL AND 
THEIR MOLECULAR CHARACTERIZATION 
Aim & objectives: 
        Hepatitis B and hepatitis C virus are the two hepatotrophic blood borne viruses of 
significant global and public health importance. They have similar modes of transmission by 
parenteral,sexual, and perinatal modes. They cause liver related mortality and morbidity. 
Worldwide over 2 billion people have been infected with HBV and more than 350 million have 
chronic HBV infection. The aim of the study is to determine the seroprevalence of Hepatitis B 
and C virus and providing genotyping of both the viruses at, Thanjavur tertiary care hospital. 
Materials and methods: 
Blood samples were collected from 194 patients who registered at OPDs and admitted at 
IPDs at tertiary care hospital Thanjavur Medical college Hospital, Thanjavur during October 
2014 to July 2015.All the samples were initially tested for Hepatitis B surface antigen and 
antibodies to Hepatitis C by using ERBALISA ELISA kit.Positive samples and randomly 
selected negative samples were further processed for HCV RNA and HBV DNA identification 
by Real time PCR.Positive samples by Real-time PCR were further processed for genotyping 
analysis. 
Results: 
Out of 194 samples, eight samples were positive for HBsag and five samples were 
positive for antibodies to HCV.Prevalence of Hepatitis B virus was 4.1% and prevalence of 
Hepatitis C Virus was 2.6%.Out of eight positive samples one sample was positive for HBV 
DNA and out of five positive samples ,3 samples were positive for HCV RNA by Real time 
PCR. Genotyping for Hepatitis B virus was genotype C and for HCV was genotype 1 &3.There 
was no significant difference for age and sex in this study. 
Conclusion: 
This study estimates the seroprevalence of Hepatitis B and Hepatitis C for both the sexes 
in patients attending tertiary care hospital. The seroprevalence of Hepatitis B was 4.1% 
and Hepatitis C was 2.6% Seroprevalence study estimates the magnitude and dynamics of 
disease transmission. Moreover knowing about the genotypes in the community helps in 
the development of future vaccine. Further studies of genotype distribution will helps in 
the development, adaptation and prevention strategies. Early diagnosis prevents the 
disease progression and further complications.  
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1 .INTRODUCTION 
Hepatitis means inflammation of the liver. It is caused by different viruses such 
as Hepatitis A, B, C, D and E. 1Hepatitis B virus (HBV) and Hepatitis Cvirus (HCV) are 
the two most common blood borne, Hepatotropic viruses. HBVand HCV are important 
causes of Liver related mortality and morbidity. Hepatitis Band Hepatitis C are 
significant public healthproblems especially in developing countrieslike India.2 
        HBV is a partially double- stranded, enveloped DNA virus belongs to the family 
Hepadnaviridae.3HBV causes a spectrum of disease from self - limited hepatitis to acute 
fulminant and chronic hepatitis which may results in complications like Liver cirrhosis 
and Hepatocellular carcinoma.4WHO estimates that nearly 2 billion people are infected 
worldwide, more than 350 million people are suffer from chronic HBV infection.5Based 
on the prevalence of Hepatitis B surface Antigen (HBsAg) ,countries are classified into 
high endemicity (>8%), intermediate (2-7%), and low endemicity (<2%).HBV 
prevalence in India is in intermediate range.6Prevalence of Hepatitis B surface antigen 
(HBsAg) in India varies from 1 to 13 %, with an average of 4.7%.High prevalence rates 
of HBsAg has been noted among the Indian tribal population.7HBV has also been called 
Type b hepatitis, serum hepatitis, Homologous serum jaundice.1Hepatitis B is a vaccine 
preventable disease and an effective vaccine is available since 1982.8 
Hepatitis C virus (HCV) is a positive stranded RNA virus belonging to genus 
Hepacivirus in the family Flaviviridae.It is the major cause of chronic liver disease 
leading to cirrhosis of liver and hepatocellular carcinoma.9World health organization 
(WHO) estimated that180 million people area affected worldwide.10Studies in India 
stated seroprevalence of HCV is 1.8% among the general population.11HCV was the first 
virus identified in 1989 by molecular biology techniques after extensive testing of serum 
from experimentally infected animals.12 
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2. HEPATITIS B VIRUS 
2.1.HISTORY 
Epidemic jaundice was first described by Hippocrates in the fifth century 
B.C.The first recorded cases of Hepatitis B was discovered after the administration of 
small pox vaccine containing human lymph to shipyard workers in Germany in 1983.13In 
1940 , British doctor,F.O. MacCallum observed a larger outbreak of Hepatitis in soldiers 
received yellow fever vaccine containing human serum. He coined the terms Hepatitis A 
for the disease which is spread by food and water contaminated with fecal material and 
Hepatitis B for the form that is transmitted by exposure to contaminated blood.14In the 
late 1950,Dr Baruch Blumberg,collected blood samples from the populations all over the 
world for his research work in polymorphism in blood proteins.15In 1963,Dr. Baruch 
collected sera from the patients who had received multiple transfusions (hemophilia and 
leukemic patients).These samples were tested for the presence of isoprecipitins using a 
panel of 24 sera from normal individuals. Two of the hemophilia sera formed a clearly 
defined precipitin line with one of the panel sera from an Australian aborigine,but not 
withothers. This new protein has been called as Australian antigen. In 1970 D.S Dane 
discovers whole Hepatitis B virus in blood samples by electron microscopy.16Dr. 
Blumberg received the Nobel Prize in medicine in 1976 for this discovery. 
2.2. CLASSIFICATION 
The family,Hepadnaviridaeis classified into two genera namely 
Orthohepadnavirus and Avihepadnavirus.The genus Orthohepadnavirus comprises the 
mammalian viruses which includes hepatitis B virus(HBV),Woodchuckhepatitis virus 
(WHV),Ground squirrel hepatitis virus(GSHV).The genus Avihepadnavirusescomprises 
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the avian viruses ,which includes Duck hepatitis Bvirus (DHBV),Heron hepatitis B virus 
(HHBV).17 
2.3. MORPHOLOGY AND PHYSICOCHEMICAL PROPERTIES 
Under the Electron Microscope, Hepatitis B patients show three distinct 
morphological forms.The most abundant form are small,spherical and non- infectious 
particle1,measuring 20 nm in dm.18It is found in higher concentrations and is about 1013 
particles per ml.The second form is tubular, filamentous forms with various lengths with 
a dm of 22nm.1The third morphological form is the spherical,double shelled particle 
known as the infectious HBV virion or Dane particle. It is about 42 nm in diameter.It 
consists of icosahedral nucleocapsid, about 30 nm in dm.The nucleocapsid contains the 
circular,partially double stranded genomic DNA about 3.2 kb in length.It is covalently 
linked to an endogenous DNA polymerase (reverse transcriptase) enzyme.19The 
Nucleocapsid is surrounded by a lipid bilayer in which the three envelope proteins 
namely small(S), medium (M), and large (L) are anchored as transmembrane 
proteins.They play a major role in HBV morphogenesis and infectivity.20 
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Figure No.1.Structure of HBV  
GENOMIC STRUCTURE AND FUNCTION 
The genomic size of HBV is ~3,200 base pairs.It consists of partially double 
stranded, relaxed –circular DNA (RC-DNA).It consists of partially double stranded 
called negative strand and an incomplete non-coding strand called as positive strand.21 
The main four overlapping reading frames in the HCV viral genome are S, C, P, 
and X22S ORF codes the viral surface envelope protein,the HBsAg.It can be structurally 
and functionally divided into pre –S1, pre S2, and S regions .The C–ORFencodes either 
the viral nucleocapsidHBsAg or Hepatitis B e antigen(HBeAg) depending on whether 
translation is initiated from the core or precoreregions, respectively.23The function of 
HBeAg is to promote persistent infection.24The polymerase (pol) is a large protein 
encoded by P-ORF.It is functionally divided into three domains: the terminal protein 
domain, which is involved in encapsidation and initiation of minus- strand synthesis; the 
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reverse transcriptase (RT) domain involved in genomic synthesis, and the Ribonuclease 
H domain, involved in the replication .22 
 
 
Figure No.2  
NON STRUCTURAL PROTEINS 
a) HBsAg 
Formerly called Australian antigen or hepatitis –associated antigenis an antigenic 
determinant found on the surface of the virus .It also makes up sub viral particles 
(SVP),22-nm spherical and tubular particles.HBsAg can be detected in the serum 30 to 
60 days after exposure to HBV and persists for variable periods.HBsAg is not infectious 
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.Only the complete virus (Dane particle) is infectious. HBsAg is antigenically 
heterogeneous, with a common antigen a and two pairs of mutually exclusive antigens 
d,y,w and r. It results in 4 major subtypes:adw ,ayw, adr and ayr.25 
b) HBcAg 
It is the major constituent of the nucleocapsid.It is essential for viral replication.26It is 
the nucleocapsid protein core of HBV.HBcAgis not detectable in serum,but it can be 
detected in liver tissue of persons with acute or HBV infection.25It has either 183 or 185 
amino acids depending on the genotype of the virus.27It is thousand fold more 
immunogenic than HBeAg.28 
c) HBeAg 
It is detected in the serum of patients with high viral titers and indicates high 
infectivity.25 It may play a role in perpetuating viral infection during perinatal 
transmission, resulting in chronic infection29.HBeAg is a non-particulate secretory 
protein discovered by Magnius and Espmark in 1972.30 
2.4. REPLICATION 
I. ATTACHMENT 
Attachment of mature HBV virion to a receptor at the surface of the hepatocyte is 
the primary phase of the replication.It is mainly due to the pre-S domain of the surface 
protein.31Numerous host receptors were identified, namely the transferrin receptor,the 
asialoglcoprotein receptor molecule, and human liver endonexin. But the mechanism of 
HBsAg binding to a specific receptor to enter cells has not been eatablished.1 
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Figure No.3.Replication of HBV 
II. ENTRY 
It involves the following steps 
1. Removal of 5’terminal redundancies from the negative strand and removal of     
covalently bound polymerase 
2. Removal of the RNA primer 
3. Completion of the positive DNA strand 
4. Linkage of the 5’ and 3’ends of each strand by DNA ligase.15 
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III. TRANSCRIPTION AND TRANSLATION 
I. The RNA polymerase II which is essential for the mRNA synthesis in the cell 
whch helps to initiate transcription.The unsplicedcDNA transcript has got a 
polyadenylated 5’cap structure .The different 5’caps in 2 species shows a 
transcript density of 3 to 3.5 kb.genetic matter.There are different types of RNAs 
like precore and pre genomic .The messenger RNA takes part in the synthesis of 
core and polymerase. The transcription template formed by pregenomic RNA is 
for reverse transcription. The precore gene product translation is maintained by 
precore RNA. The pgRNA start codons initiate the translation of polymerases 
helped by the scanning mechanisms of the ribosomes .The subgenomic RNA of 
2.5 kb helps the trandslation of the large HBsAg [L HBsAg] the small HBsAg 
and middle HBsAg translated from various RNAs of 2.1kb. 0.8kb RNA serves as 
a template for the synthesis of HBxAg protein. 
 
IV. ASSEMBLY AND MATURATION 
Replication of HBV begins with encapsidation of the genome. The packaging signal 
is a Cis-acting element referred to as epsilon, which contains a stem loop structure.32 The 
terminal protein of the pol interacts with the epsilon and along with the core protein 
forms the nucleocapsid. The pol mediates the reverse transcription of the pg RNA to 
minus-strand DNA after encapsidation and subsequent positive-strand synthesis.Thus the 
circular form of the DNA is completed.33 
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V. BUDDING AND RELEASE 
The envelope proteins is integrated  as integral membrane proteins into the lipid 
membrane of the endoplasmic reticulum(ER).The new, mature, viral nucleocapsids 
undergoes two different intracellular pathways, one of which leads to the formation and 
secretion of new virions and the other leads to the amplification of viral genome .In the 
virion assembly pathway, the nucleocapsid reach the ER and associate with the envelope 
proteins ,bud into the lumen of ER, and finally secreted through the Golgi apparatus into 
the extracellular milieu.1 
2.5. GENOTYPES 
Based on genetic sequence hepatitis B virus is classified into eight genotypes(A-
H).The recently detected new genotypes include I and J.The further division of the HBV 
into sub genotypes .The nucleotide difference among genotypes shows more than 8% 
and subgenotypic variation from 6-8%.The subgenotypic division includes A-D and F 
genotypes.Genotypes E ,Hand G doesn’t have any sub genotypes. The sub-genotypes 
and genotypes are different in various domains like disease distribution and duration, 
course of the disease, treatment response and prognosis of the disease  34 
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Table 1.Molecular epidemiology versus Geographic Distribution of HBV 
GENOTYPE SUBTYPE GEOGRAPHIC 
LOCATION 
A 
A1 
A2 
A3 
Sub Saharan Africa 
Northern Europe 
Western Africa 
B 
B1 
B2-B5 
B6 
Japan 
Taiwan,China,Indonesia 
Alaska, NorthernCanada 
C 
C1-C3 
C4 
C5 
Taiwan,china, Japan, Asia 
Australia 
Philippines, Vietnam 
D D1-D5 Africa,Europe,India 
E  Restricted to west Africa 
F F1-F4 Central and south America 
G  France,Germany,United states 
H  Central America 
I  Laos, Vietnam 
J 
 Japan 
 
2.6. CLINICAL COURSE 
I. ACUTE HEPATITIS B 
Acute infection is common in adults than in children. The incubation period of acute 
hepatitis infection ranges from 45 to 160 days.50% of adults are asymptomatic in acute 
infectious stage.It is classified into three phases. 
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 Pre-icteric or prodromal phase 
It is from initial symptoms to onset of jaundice.It usually lasts for 3 to 10 days. 
Clinical symptoms are characterized by insidious onset of fever, malaise, anorexia, 
vomiting, right upper quadrant abdominal pain, arthralgia, arthritis and dark colored 
urine. 
 Icteric phase 
Usually lasts for 1 to 3 weeks. Clinical symptoms are jaundice, hepatic tenderness 
and hepatomegaly. 
 Convalescence phase 
Malaise and fatigue lasts for weeks or months. Jaundice, anorexia and other 
symptoms disappear.25 
 
II. CHRONIC HEPATITIS B 
Chronic HBV infection is defined as the presence of HBs Ag in the serum for at least 
6 months.35Most of the patients are asymptomatic during chronic infection.They are 
capable of infecting others and they referred to as carriers.Chronic infection may develop 
to chronic hepatitis, cirrhosis, liver failure, and hepatocellular carcinoma.It is responsible 
for most HBV –related mortality and morbidity.5% of adults are in the risk of acquiring 
chronic HBV infection, but 90% of infants are become chronically infected when they 
acquire infection from the mothers at the time of birth.25Chronic HBV infection includes 
four phases. 
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 a) Phase of Immune tolerance 
 b) Phase of Immune active or immune clearance 
 c) Phase of Inactive HBsAg carrier state  
 d) Phase of Reactivation  
a) Phase of Immune tolerance:  
 It shows high levels of HBeAg , normal  ALT levels, and Hepatitis B viral DNA 
>20,000 IU/ml.It occurs mostly in individuals who acquired HBV infection by perinatal 
transmission. 
b) Immune active phase: 
 It shows positive for HBeAg or HBeAb, with high levels of serum ALT levels 
and HBV DNA>2000 IU/ml.It is present in individuals who acquired infection in early 
child hood. 
c) Phase of Inactive HBsAg carrier state: 
This stage is identified by the absence of HBeAg with the presence of HBeAb, 
normal serum ALT levels and Hepatitis viral DNA<2000 IU/ml. 
d) Phase of Reactivation : 
This phase refers to inactive phase or at the stage of resolved hepatitis B infection . It 
is characterized by elevated serum ALT levels, HBeAg negative and HBVDNA levels 
>2000 IU/ml.3637 
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TABLE 2: CHB at different stages(molecular characteristics and stages of chronic 
hepatitis b) 
Phase ALT HBsAg HBeAg HBeAb HBVDNA Liver 
histology 
Immune tolerance Normal Present Present  Absent >2000 Usually 
normal or 
mild 
inflammation 
Immune clearance Elevated Present Present Absent >2000 Active 
inflammation 
Inactive HBsAg 
carrier 
Usually 
normal 
Present Absent Present <2000 Mild 
inflammation 
to inactive 
cirrhosis 
HBeAgNeg.CHB Periodic 
flares 
Present Absent Present >2000 Active 
inflammation 
Occult hepatitis B Can be 
elevated 
Absent Absent Present in 
recovered 
HBV 
infection  
<2000 Normal to 
cirrhosis and 
HCC 
 
III. HEPATOCELLULAR CARCINOMA 
Persons with chronic hepatitis will develop hepatocellular carcinoma.Primary liver 
cancer is the eighth most common cancer in the world.HBV is responsible for 80% of 
liver cancers. 
IV. FULMINANT HEPATITIS B 
It is a rare condition.It develops in about 1% of cases. Survival rate in adults is 
uncommon. 
V. EXTRA-HEPATIC MANIFESTATIONS OF HBV 
It is seen in 10-20 %of patients.It includes transient serum sickness-like 
syndrome,acute necrotizing vasculitis, and membranous glomerulonephritis.1 
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VI. OCCULT HEPATITIS B 
Occurance of Hepatitis B viral DNA in liver or serum of the patient in the 
absence of HBsAg is called Occult hepatitis B. Its frequency is higher among patients 
with hepatocellular carcinoma following an HBV infection and patients with 
longstanding hepatitis C infection, seronegative HBV individuals.The importance of 
occult hepatitis B occur in the context of HBV transmission during organ transplantation 
and blood transfusion. The prevalence of HBV infection and HBV DNA assays 
determines the diagnosis of occult hepatitis B in the population.38 
2.7. PATHOGENESIS AND IMMUNITY 
The pathogenesis of Hepatitis B is due to the interaction of the virus and the host 
immune system.Various HBV derived peptides, located on the surface of the hepatocytes 
are recognized by activated CD4 and CD8 lymphocytes.This leads to immunologic 
reaction,impaired immune reactions, or a relatively tolerant immune status,resulting in 
chronic hepatitis.The first step in HBV infection involves a specific non-cell type 
primary attachment to the cell-associated heparin sulphate proteoglycans.This is the 
reversible attachment .This is followed by an irreversible binding of the virus to a 
specific,unknown hepatocyte –specific receptor.This step requires activation of the 
virus,resulting in exposure of the myristoylated N-terminus of the l-protein.This is the 
vital determinant for infectivity.39 
2.8. EPIDEMIOLOGY 
HepatitisB is the most prevalent infectious disease globally. The world wide 
burden of hepatitis B is calculated around 350 million ,the chronic hepatitis B viral 
infection shows following prevalence statistics ie low (<2% ) intermediate around 3-7 % 
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and high shows more that 8% . The data regarding occult hepatitis B viral infection and 
HBeAg non-reactive hepatitis B is yet to be calculated.40Hepatitis B is moderately 
endemic in eastern and southern Europe,the Middle East, japan and part of South 
America.41Low endemicity is seen in North America and Australia.42The predominant 
routes of transmission vary according to the endemicity. High endemecity areas shows 
post partum route as the main mode of transmission but in low endemic areas sexual 
contact predominates. HBV is classified into 7 genotypes.Genotyping provides an 
epidemiological clue by, that genotype B and C are common in high endemic areas of 
perinatal exposure .Other genotypes are observed in regions of horizontal exposure.42 
MODES OF TRANSMISSION 
Most common modes of transmission are perinatal, sexual and parenteral / 
percutaneous transmission. Other modes are needle sharing, house hold (non-sexual), 
occupational or related to health care.Blood and serum shows the highest concentration 
of Hepatitis B particles. 43 
 Peripartum Transmission 
Peripartum transmission of hepatitis B from mothers to babies is common. From 
worldwide stastistics it is being one of the most common routes for disease 
transmission.44 The frequency of occurance of hepatitis B is nearly 20 % among infants 
those who born with HBsAg positive mothers and nearly 90% in HBeAg positive 
mothers. 45 
 Transmission through sexual route 
Sexual contact is the main mode of HBV transmission.46 Persons having 
contacts with long standing HBV positive infection shows a higher incidence of 
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Hepatitis B viral infection. Most of the acute Hepatitis B positive cases shows history of 
exposure to multiple Sexual partners .The incidence of Hepatitis B in men who have sex 
with men are high compared to others. 47 
Unscientific behaviours like sharing of needles and syringes leads to higher 
number of HBV cases among injection drug abusers. 
 Nosocomial transmission  
Nosocomial infections are one of the most common sources of new HBV incidence 
around the globe.The recognized modes of transmission are patient to patient, provider to 
patient and patient to provider. Before the implementation of vaccination for health care 
workers, patients to provider transmission were common. The reason for patient to 
patient HBV transmission was mainly by the use of unsterilized equipments used for 
injections and other procedures  
 Transmission via intravenous route 
The spread of hepatitis B virus through blood and blood products has been reduced 
due to adequate screening of donors.Universal protocol is being followed in all blood 
banks to ensure the same. 48 
2.9. HBV MUTATIONS 
 Inspite of vaccinations, HBV infections are still common worldwide. The virus 
replicates by reverse transcription by viral polymerase lacking proof reading ability. This 
results in the emergence of mutant viruses. A number of well characterized HBV 
mutations have been identified, leading to vaccine failure, loss of HBV detection by 
diagnosticassays, increased viral replication leading to hepatic damage, and resistance to 
antiviral agents. 
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 Escape mutant: The use of HBV vaccines will control and eradicate 
HBVinfection. This mutant has been detected in vaccinated individuals. This is 
due to altered HBsAg resulting in HBV infections that escaped vaccine induced 
immunity. These strains are known as HBV escape mutants. 
 Basal core promoter mutation: This is due to the changes in transcription 
mechanism, leading to reduction in HBeAg levels with a consequent increase in 
viral replication. 
 Pre-core mutant: This is due to the translational stop codon eliminating 
HBeAgproduction, resulting in HBeAg negative disease.49 
2.10. LABORATORY DIAGNOSIS 
Diagnosis is based on clinical, laboratory,epidemiologic findings. Laboratory 
diagnosis is based on serological and virological markers. 
1. SEROLOGICAL MARKERS 
 Hepatitis B surface antigen(HBsAg) 
It is the most commonly used test for diagnosing acute HBV infections or 
detecting carriers.28It is detected as early as 1-2 weeks or as late as 11-12 weeks after 
exposure. Its presence indicates high level of replication.50It is detected by solid phase 
immune assays with unlabeled anti-HBs as the carrier and labeled anti-HBs for detection 
in the liquid phase.Originally,radioactive iodine 125 was used as label but, now enzymes 
are preferred(EIA) which generate a colored product.15 
 Hepatitis B core antigen(HBcAg) 
It is expressed only infected hepatocytes, because it is an intracellular antigen. It 
cannot be detected in the serum.  
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 Anti-hepatitis b core antibody (HBcAb) 
Its presence indicates past or current exposure to hepatitis bvirus. It can be 
detected in the serum.  Anti-hepatitis b core antibody appears within the first month after 
HBsAg is detected. It is a marker of acute infection. It is the only serological marker 
detected in the serum during the window period .HBcAb is present in the following 
conditions 
  window period  
 Individual recovered from acute hepatitis B virus infection. 
 Individuals with chronic hepatitis in whom HBsAg has reduced to low 
levels. 
 Hepatitis B e antigen (HBeAg) 
 It is not important for replication, but its presence indicates immune tolerance, 
high level viral replication,and high potential for transmission.It is detected six to twelve 
weeks after exposure.51 
 Anti-HBs 
It is a protective and neutralizing Antibody. Its presence indicates recovery and 
immunity against reinfection. It can also be acquired as an immune response to Hepatitis 
B vaccine or passively transferred by the administration of hepatitis B 
immunoglobulin.28 
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TABLE: 3 Clinical Interpretation of Hepatitis B Serological Markers (diagnostic 
approach to hepatitis b virus) 
HBsAg HBc-IgMAb 
Total 
HBcAb HBeAg HBeAb HBsAb 
HBV 
DNA 
 
Interpretation 
+ + + -/+ - - +/++ Acute HBV infection 
+ - + + - - +++ 
Chr.HBeAg positive 
infection 
+ - + - + - ++/+++ Chr.HBeAgNeg.infection 
+ - + - + - -/+ Inactive HBV carrier 
+ - + - + + - 
Resolved infection with 
immunity 
- - - - - + - 
Immune to HBV by 
vaccination 
- - + - - - - 
Three possible 
interpretations 
 
 
1. Ongoing chronic infection HBV infection with very low HBsAg titers 
2. Recovered from distant HBV infection with very low HBsAb titers 
3. False positive HBcAb test result 
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                                   Figure 4: Serological markers 
21 
 
2. MOLECULAR METHODS  
Molecular methods are mainly used to detect nucleic acids. They are performed in 
three ways  
1. Target amplification 
2. Signal amplification  
3. Recent methods. 
1. TARGET AMPLIFICATION  
 Polymerase Chain Reaction 
It can synthesize millions copies of interest segment in short time. It has 
sensitivity of detecting 50-200 IU /ml of HBV DNA, but the risk of contamination is 
high. 
 Real-Time Polymerase chain reaction 
It is a superior technology.it can able to detect and quantify hepatitis viruses 
based on nucleic acid amplification without post PCR handling. It has a sensitivity of 
detecting 5-10 IU/ml of HBV DNA. It has high sensitivity and specificity and it is the 
gold standard technique for HBV DNA detection. 
 Loop Mediated Isothermal Amplification 
It is a Novel and strong method for nucleic acid amplification. It is an 
inexpensive and rapid method for HBV DNA Amplification. Low time consumption, 
isothermal condition and no need of specific instrument are the advantages. 
 
22 
 
2. SIGNAL AMPLIFICATION METHOD 
 Branched DNA Amplification 
It is a type of signal amplification. It is initiated from hybridization of viral 
genome with capture extenders and label extenders. Capture extenders mediate the 
binding of targets to capture immobilized probes. Label extenders mediate binding viral 
genome target to branched DNA. 
3. NEWER TECHNIQUES 
 Biosensors: 
It is a compact analytical device incorporating biological or biologically derived 
sensing element integrated with physiochemical transducer. They are label free devices 
and it can sense specific targets through bio molecular interactions such as enzyme 
substrate reaction, receptor –ligand or antibody –antigen complexes. Various types are 
surface Plasmon resonance based method, piezoelectric based biosensor, micro 
cantilever based biosensor, electrochemical biosensor and Apta- sensors. 
 Microfluidic devices: 
It is also known as lab- on- chip capable of sample and reagent processing as 
rapid micro total analysis system. High speed PCR performed on microfluidic devices 
are capable of amplifying 500 bp fragments in just 1.7 min. 
2.11. PREVENTIVE STRATEGY: 
The key modalities available for limiting HBV infections are the   
 1) Limiting the disease transmission by changes in Behavior 
2) Hepatitis B vaccination 
 3) Immunoprophylaxis using viral antibodies 
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1. Behavior modification: 
a) Changes in sexual practice 
b) Avoid sharing of needles and syringes 
c) Blood and blood products should be screened to reduce risk of transmission.46 
2. IMMUNIZATION 
1) Active Immunization 
(a) Plasma derived vaccine  
It was produced from 22 nm HBsAg particles purified from the plasma of 
chronically infected humans .It was not accepted due to the fear of transmission of live 
HBV and other blood borne pathogens. 
(b) Recombinant vaccine 
It is produced by inserting a plasmid containing the gene for HBsAg into 
common baker’syeast (saccharomyces cerevisiae).Yeast cells then produce HBsAg 
which is harvested, highly purified and adjuvanted with aluminum phosphate and 
preserved with thiomersal.It contains 95%hbsag protein and 5% of yeast derived 
proteins.it does not contain yeast derived DNA .So the HBV infection cannot result from 
use of recombinant vaccine .It is available in two forms Recombivax HB and Engerix-
b.28 
Route: Intramuscular 
Doses: Recombivax HB should be given as three doses at 0,1,6 months and 0, 1 and 2 
months for Engerix –b.52 
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2) Passive Immunization 
The antibody against hepatitis B virus which is developed from the serum of patients 
who were suffering from acute HBV infection is used to provide passive immunization 
via immunization therapy.  
1) Newborn infants born to HBsAg positive mothers, 
2) Post needle stick,  
3) Following sexual contact in adults  
4) Liver transplantation individuals.53 
2.12. TREATMENT 
 The goal of treatment is clearance of HBV DNA to prevent the development of 
cirrhosis,liver failure and HCC.53There is no treatment for acute hepatitis B 
infection.Itdoes not require specific treatment because the infection will clear 
spontaneously in >90% of adults. Only the patients with chronic hepatitis b need the 
treatment. 
(1)ANTIVIRALS: 
 Pegylated interferon Alfa  2-a 
It belongs to a family of naturally occurring proteins .It has both antiviral and 
immunomodulatory actions. It enhances the T-cell helper activity and enhancesHLA type 
1 expression.54 
Dosage: 5 million IU, subcutaneously daily for 16 weeks. During the course of treatment 
complete monitoring of total blood count, prothrombin time, total bilirubin, ALT, AST, 
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HBsAg, anti-HBs, HBeAg and quantitative HBV DNA at 2,4,8,12,and 16 weeks is 
must.68 
 Nucleoside analogs 
Lamivudine:Dosage: 100mg once-daily.55 
 Newer antiviral agents 
Ritonavir, Adefovir,Dipivoxil,Lobucavir,Famvir,N-acetyl-Cysteine are 
the newer anti-viral agents.1 
2) ADOPTIVE IMMUNE TRANSFER 
It is a newer approach to terminate the HBV infection by bone marrow transplant 
from a hepatitis b immune donor56 
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    3. HEPATITIS C 
3.1. HISTORY: 
 By the mid-1970, transfusion associated hepatitis was classified as non-A,non- B 
hepatitis (NANBH). Subsequently, experiment on chimpanzee demonstrated the chronic 
nature of NANBH. Breakthrough occurred in1988, by workers at ChironCorporation 
declared the discovery of viral antigens responsible for post transfusion non-A, non-B 
hepatitis. They extracted all nucleic acid from known infectious serum. From this they 
formed complementary DNA fragments by using reverse transcriptase with random 
primers. This process yielded approximately 6 million sequences complementary to 
random segments of nucleic acid found in the infectious serum. These sequences are then 
inserted into phage vectors and expressed in Escherichia coli. The resulting polypeptide 
was tested with serum from patients with chronic non-A, non-B hepatitis to detect 
reactivity with serum antibodies. The polypeptides were also screened with control 
specimens of non-infected serum. By this way, they had screened millions of such 
specimens. Out of this one was found to react with antibodies in infected serum but not 
with control serum.48In 1989, Hepatitis C virus was discovered. 
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3.2. MORPHOLOGY 
The Hepatitis C virus is an enveloped RNA virus with a diameter of about 
50nm.It belongs to the familyFlaviviridae and the genus Hepacivirus.49 
 
Figure No.5.Structure of HCV  
GENOMIC STRUCTURE 
HCV contains a single stranded,positive –sense RNA virus, which is approximately 9.6 
kb. The HCV RNA genome consists of three distinct regions. 
 5’UTR or non- coding region; 
 Long open reading frame (ORF) which approximately contains  9000 nt, and  
 3’UTR.50 
5’UTR: 
 Three hundred and forty one nucleotides are present in the 5’UTR .It is the most 
conserved region of the genome. It is folded into a complex secondary RNA structure. It 
includes internal ribosome entry site. The IRES is necessary for the polyprotein 
translation.51 
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3’UTR: 
It contains approximately 200 nucleotides and it is shorter and less structured 
than 5’UTR.It is essential for replication.52It consists of three segments namely 
 short poorly conserved sequence 
  poly(u)/polypyrimidine tract 
 Highly conserved segment.49 
 
GENOMIC PROTEINS 
It includes three structural proteins, six non-structural (NS) proteins,frame shift 
`F’ protein anda small protein. The structural proteins include HCV core protein and 
glycosylated envelop proteins E1 and E2.The non-structuralproteins which constitutes 
HBV genome are NS5A, NS4B, NS4A, NS3, NS2 and NS5B 
THE STRUCTURAL PROTEINS 
HEPATITIS B VIRAL CORE `C’ protein  
HBV viral capsid is mainly formed by core c protein which is a basic RNA –
binding protein.53Itinteracts with cellular proteins and plays an important role in viral 
replication.54 
Envelope glycoproteins 
E1 and E2Envelope glycoproteins areimportant for viral entry and fusion.55 
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Protein F 
The ribosomal frameshift occurs in the viral polypeptide at the N- terminal core-
coding region leads to the development of alternate reading frame protein or F protien 
polypeptide. It is produced during the infective phase of the virus.56 
Figure 6: Genomic structure of HCV
 
 
Non-structural proteins  
 NS2: It is a non-glycosylatedtransmembrane protein. It plays role in replication 
of the virus.57 
 NS3: It forms the main target for the antiviral drug development against HCV. C 
terminal RNA helicase and n terminal serine protease are coded by NS3  
 NS4a:It act as a cofactor for ns3 protease and helps to form a stable complex with 
NS3.58 
 NS4b: It is an integral membrane protein. Itregulates viral and host translation 
process. It causesimpairment of ER function and plays animportant role 
carcinogenesis of HCV.59 
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 NS5a: It is a phosphorylated zinc metalloprotein. It plays an important role in 
regulation of cellular pathways such as membranelocalization, 
transcriptionalactivation, and assembly of replication complex. It also plays a 
role in interferon resistance by inhibiting RNA activated protein kinase. 
 NS5b: It is an RNA dependent RNA polymerase. It is responsible for replication 
of the virus. The first step is the formation of negative strand complementary 
RNA and this will act as a template for the subsequent positive strand HCV 
RNA replication.60 
3.3. REPLICATION 
VIRION AND LIPOPARTICLE OF HCV VIRUS 
The following genomic particles constitute HCV virus. ProteinsE1 and 
E2,envelope glycoproteins, core antigen and HCV RNA genome.The viral nucleocapsid 
formed by the interaction of theRNA genome with the core protein,which is surrounded 
by a viral envelope rich in glycoproteins E1 and E2 and phospholipids.The receptor 
mediated viral entry with binding and fusion mainly depends upon the integrity of E1 
and E2. 
VIRAL ATTACHMENT 
Initial viral attachment involve glycosaminoglycan (GAGs) and low density 
lipoprotein receptor (LDL-R), interact with viral envelope proteins. 
ENTRY 
Entry depends on binding of E2 with CD81.Other cellular factors and entry 
factors which helps in the entry are scavenger receptor class B type 1(SRB1),tight 
junction proteins,Claudin -1(CLDN1) and occluding (OCLN).Recent studies shows 
31 
 
some newer viral entry particles epidermal growth factor receptor (EGFR),Ephrin 
receptor A2 (EphA2) ,receptor tyrosine kinases (RTK),niemann-pick c1 –like 1 
cholesterol absorption receptor (NPC1L1). The endocytosis of HCV into the target cells 
are pH. dependent and clathrin mediated. 
 
VIRAL FUSION  
After the viral entry into the target cell through endocytosis, pH dependent fusion 
of HCV particle with the membrane leads to formation of free viral genome inside the 
cytoplasm of target cell.  
REPLICATIONANDTRANSLATION OF HCV RNA 
Positive strand HCV  RNA acting as a template for the translation of the HCV 
polyprotein inside the rough ER. 5’NTRand IRES mediates the translation process. 
Cellular and viral proteases refine the precursor protein developed after the HCV 
translation.It leads to generation of 10 viral proteins namely core and envelope 
glycoproteins,E1 and E2,P7,NS2,NS3,NS4A,NS4B,NS5A and NS5B.These proteins are 
associated with a membranous web which includes double –membrane vesicles 
containing HCV nonstructural ,HCV RNA ,ER membranes and lipid droplets. 
Membranous web is the principal site of replication. Positive strand RNA genome act as 
a template for the NS5B RNA-dependent RNA polymerase to produce negative strand 
template intermediate which further produce positive strand RNA genome. 
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Figure No.7.Replication of HCV 
VIRAL ASSEMBLY AND RELEASE 
The association of LDs and HCV core is vital in viral assembly, linked to NS5A 
and other members of the replication complex by interaction with NS2.Vipoporin p7 is 
necessary for the production of stable viral particles coated with E1 and E2.They are 
glycosylated in ER and new virions are released. 
3.4.GENOTYPES 
HCV is classified into eleven major genotypes, namely 1-11, further classified into 
many subtypes namely a,b,c and 100 different strains numbered 1, 2,3 based on the 
genomic sequence heterogeneity. 
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 Genotype 1-3 
 It is distributedworldwide. 
 Types 1a and 1b are the most common. 
 It accounts for 60% of global infections. 
 Theymostly predominate in northern Europe, SouthernEurope, North America 
and Japan. 
 Type 2 is less frequent than type 1. 
 Type 3 is endemic in South East Asia. 
 Genotype 4  
• It is distributed in Middle East, Egypt and central Africa. 
 Genotype 5 
• It is exclusively found in South Africa 
 Genotype 6-11 
• They are mostly found in Asia.49 
Genotyping is necessary to know the response to antiviral treatment.Poor 
prognosis isassociated with Genotype 1 andgood prognosis isassociated with Genotypes 
2 and 3.61 
3.5.CLINICAL COURSE 
I. Acute HCV infection 
The incubation period is 6 to 10 weeks. Most of the patients are asymptomatic. 
Symptoms areanorexia, nausea, vomiting, abdominal discomfort, fever &fatigue .70%-
90% of the patients with acute infections will become chronic carriers.49 
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II. Chronic hepatitis C 
It is defined as persistence of disease without any improvement for at least six 
months.HCV is self-limiting in 15 -25% of patients, and the infection is resolved 
spontaneously.75 -85% of infected patients develop chronic hepatitis. Chronic hepatitis c 
progresses to cirrhosis and hepatocellular carcinoma.57 
COMPLICATIONS 
III. Cirrhosis. 
The features of cirrhosis include ascites, portalhypertension, upper gastrointestinal 
bleeding, Hepatorenal syndrome and hepatic encephalopathy. 
IV. Hepatocellular carcinoma 
Approximately 1-5% of chronic hepatitis c patients develop hepatocellular carcinoma. It 
iscommon in patients with chronic Hepatitis C with cirrhosis.49 
V. Extrahepatic manifestations 
Chronic HCV infections are associated with numerous extrahepatic manifestions.The 
most common extrahepatic manifestation is mixed cryoglobinemia.This manifestations 
are mainly due to immune complex deposition in various organs. Other manifestations 
include membranoproliferativeglomerulonephritis, lichenplanis and vitiligo.62 
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3.6.EPIDEMIOLOGY 
 Prevalence  
Global prevalence ofHepatitis C virus is 2-3%.The prevalence of HCV is highest 
in Africa and Middle East. Majority of the cases were found in India, China, Egypt and 
Pakistan. NorthAmerica, Australia and japan report lower prevalence.58 
 Modes of Transmission 
The most common mode of transmission is through direct percutaneous 
exposures to blood. Bloodtransfusion, transplantation from infectious donors and 
injecting drug use are the commonest modes of transmission.It is less transmitted by 
single small dose percutaneous exposure (accidental needle sticks) or by mucosal 
exposures to blood (birth to an infected mother, sex with an infected partner).59 
One genomic variant of HCV is known as Quasispecies.This variant is related to 
HCV but it’s a distinct virus and leads to high mutational rate.Hence Identification of 
genotypes and subtypes is a necessary for treatment and epidemiological study.62 
3.7.LABORATORY DIAGNOSIS  
HCV is diagnosed both by serological and molecular assays. 
A. SEROLOGICAL DIAGNOSIS 
 Rapid Immunoassays: 
The principle behind rapid immunoassay is mapping of HBV core antigens, 
NS3, NS4, and NS5. It is used asa surveillance measure for HCV transmission in the 
community.  
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The use of this test is limited in the context of HIV infection and severe HCV 
infection. The higher incidence of false negative results limiting its use in large 
population.60 
 Enzyme Immunoassays: 
The main screening assay for detecting anti- HCV is enzyme immunoassay.61The 
first generation anti-HCV test (EIA-1) contains a single HCV recombinant antigen 
derived from the non-structural NS4 gene, namely c100-3.But it lacks optimal sensitivity 
and specificity. So it was replaced by EIA -2.It contains HCV antigens from the core and 
the NS3 genes in addition to NS4 –derived antigen. It is a multiantigen assay. The 
disadvantage of this EIA is that it fails to detect antibodies in immunocompromised, 
organ transplantation recipients.Currently, third generation EIA-3 has been used to detect 
anti-HCV antibodies. It contains core and NS3 antigens with an addition NS5 antigen not 
present in the EIA-2.The mean time to seroconversion in transfusion recipients was 
shortened by 2 to 3 weeks when compared to 10 weeks with EIA-2.62 
 Immunoblot Assays: 
It is a conformation test for antibodies against HCV in those who showed enzyme 
immunoassay positivity for the virus . In this test nitrocellulose membrane strips used 
show various HCV antigens as strips and bands .The presence of 2 reactive bands are 
seen in patients with HCV positivity.In cases with intermediate infections shows only 
one reactive band. The tests like EIA and RIBA are no longer used because of its high 
sensitivity and specificity.63 
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 HCV core antigen assay: 
It is an immunoassay based on phenomenon of chemiluminescence in an 
automated platform. In this test HCV core antigens are detected using monoclonal 
antibody coated micromolecules.  The use of this test is limited to the first 14 days of 
acute HCV infection. Approximately 1000 IU/ml of HCV viral particles can be detected 
as a lower limit of this assay. The core antigen testing is an important diagnostic tool in 
high risk HCV population. Its sensitivity is around 80- 98 % and specificity ranges from 
97-100 %. 
Advantages: 
 It is an immunoassay  
 It does not require sample processing as in molecular assays. 
 Positive result confirms active infection 
Disadvantage: 
 It has a lower sensitivity than NAT.64 
B. MOLECULAR DIAGNOSTICS 
 Detection of HCV RNA : 
HCV-RNA is detected in the serum as early about 1 to 3 weeks after infection. It 
is detected before the appearance of anti-HCV antibody. Its presence indicates ongoing 
viral replication.it is the gold standard for HCV diagnosis.63It is also used to determine 
the viral load both prior to and during antiviral treatments.68 
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HCV RNA Detection  
1. More sensitive before sero-conversion 
2. Helps to delineate resolved infection from active infection.  
3. In high risk groups with chronic carriers of HCV infection who are antibody negative   
 HCV RNA detection via qualitative methods: 
 This test helps to assess the circulating HCV RNAs and their presence in the 
blood. The following are the key determinants behind the assay 
 Isolation of Viral RNA 
 Synthesis of cDNA 
  Polymerase chain reaction 
 Amplicon detection via PCR 
A. Reverse transcriptase PCR 
 It is the widely used method to diagnose HCV-RNA. It is also used to assess the 
viremia during and following anti-viral therapy.Nowadays many commercials assays are 
available to detect HCV RNA by qualitative methods.one of them is Cobas amplicor 
version 2.0. It has a lowest detection limit of 50IU/ml whatever may be the HCV 
genotype. 
B. Transcripted mediated amplification 
Principle: 
 Isolate the HCV RNA from the patients serum 
 Amplified by using two enzymes namely reverse transcriptase and t7 RNA 
polymerase. 
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 Amplicons are further detected by hybridization protection assay. Its analytical 
sensitivity is 10 IU/ml for most of the genotypes. 
Quantitative Assay:  
Qualitative assay detects only the presence or absence of HCV RNA. But the 
quantitative assay determines the HCV RNA level and gives prognostic information for 
the treatment.65 
Real-time PCR 
Real-time PCR can be used to quantify HCV RNA.It has a broad dynamic range 
of quantification. Carryover contamination is less when compare to other assays.It is 
more sensitive and it can detect 10-15 IU/ml HCV RNA. 
 Quantification of HCV RNA is useful 
 To diagnose chronic HCV infection 
 To monitor viral load to antiviral therapy 
 Document the treatment failure.65 
C. HCV GENOTYPE DETERMINATION 
Major predictor of Sustained virological response to antiviral therapies is 
considered as HCVgenotyping and HCV-RNA quantification. Sustained virological 
response is defined as testing negative for HCV RNA 6months after cessation of therapy. 
It is the gold standard for treatment response. Rapid virological response is defined as the 
patients who test negative for HCV RNA at 4 weeks. Early virological response is 
defined as the patients who test negative for HCVRNA at 12 weeks.66Genotyping is 
important to predict the treatment response and to determine the optimal duration of 
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therapy.HCV genotyping is done by genomic sequencing of core/E1 or NS5B regions, 
followed by phylogenetic analysis.67 
Newer Techniques 
Prototype nano-particle –based assay is the recent technique used for the 
detection of biomarkers. Quantum dots (QDs) and gold nano particles are the most 
commonly used nanoparticles.69 
3.8.TREATMENT 
The goal of antiviral treatment for CHC is to stop the progression of the disease, 
prevent cirrhosis and reduce the risk of HCC.68SVR is defined as undetectable levels of 
HCV RNA at least 24 week after completion of therapy.69SVR is the standard marker for 
the successful antiviral treatment in clinical trials. 
Combination of pegylated interferon plus ribavirin (PR) is the standard treatment for anti 
–HCV.70 
Protease Inhibitor: 
Bocepravir and telaprevir are the two protease inhibitors used for the treatment of 
chronic HCV genotype 1 infection. The advantage of this drug is the shorter duration of 
therapy (24 to 28 wks).71 
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4.AIM OF THE STUDY: 
To find out the seroprevalence of Hepatitis B surface antigen and Antibodies to 
Hepatitis C in patients attending tertiary care hospital. 
 
OBJECTIVES: 
 To estimate the seroprevalence of HBsAg and antibodies to Hepatitis C in 
both the sexes and different age groups in hospital based population. 
 To assess the magnitude and the important factors related to the disease 
transmission in the community. 
 To detect the Hepatitis B surface antigen and antibodies to Hepatitis C by 
Elisa. 
 To evaluate the molecular characterization for both HBV and HCV. 
 This study aimed at early diagnosis, disease prevention and treatment. 
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5.MATERIALS AND METHODS 
Place of study: Thanjavur medical college hospital, Thanjavur 
Study period: October 2014 to July 2015 
Design of Study: Prospective study 
Ethical committee: Prior approval obtained from ethical committee clearance 
Informed consent: Obtained from each patient 
Sample: Blood 
A total of 194 patients who registered at the OPDs or were admitted to the 
IPDs,at tertiary care hospital Thanjavur medical college hospital,Thanjavur,were 
included in this study during the period from October 2014 to July 2015.Institutional 
ethics committee approval for the study was obtained before the initiation of the study. A 
single blood sample was collected each patient with age group above 15 years. 
Furthermore basic demographic characteristics such as age,sex,place of domicile,socio 
economic status were also obtained. 
 The samples were processed in the central service laboratory, Microbiology 
Department,Thanjavur medical college hospital. 
For collection of the sample the following inclusion and exclusion criteria were 
considered. 
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Inclusion criteria: 
Patients who registered at the OPDs, admitted to the IPDs with clinical history of 
viral hepatitis,jaundice for evaluation and alcoholic hepatitis were included in the study. 
Exclusion criteria: 
Patient with documented past history of Hepatitis B and Hepatitis c viral 
infections are excluded from this study. 
High risk groups such as immunocompromised, IDUs were also excluded from 
the study 
Sample collection: 
 A 5-ml venous blood samples was taken aseptically from all eligible patients in 
sterile vacutainers, after taking informed oral consent. The blood was allowed to clot for 
45 min. at room temperature and serum was separated after centrifugation.The serum 
sample was stored at -20⁰C until further testing. 
Specimen Processing: 
Serum is tested for Hepatitis B surface antigen and antibodies to Hepatitis C by 
ELISAMethods. 
Detection of Hepatitis B surface antigen 
PRINCIPLE 
Hepatitis B surface antigen was investigated by enzyme immunoassay (EIA) 
using ELISA kit ERBA LISA PICO HBsAg manufactured by TRANSASIA BIO-
MEDICALS LTD.,RINGANWADA,DAMAN. ERBA ELISA PICO HBsAg test kit is a 
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solid phase immunoassay for the qualitative detection of HBsAg in human serum.Ituses 
polyclonal antibodies to HBsAg as coating materials and monoclonal antibodies to 
HBsAg as conjugate materials. Serum sample, positive control and negative control were 
added to the respective wells. Addition of positive control or HBsAg containing human 
serum will form a stable complex with the bound antibody present in the microtitre well 
and with anti-HBsAg horse radish peroxidase. A washing step will remove the unbound 
conjugate molecule. Addition of color reagent will develop blue color only in positive 
control wells and wells containing HBsAg in test specimen. Blue color changes to 
yellow after the addition of stop solution. The intensity of the yellow color is directly 
proportional to the presence of bound HBsAg in the respective wells. 
PROCEDURE 
• Bring all the reagents and test specimen to the room temperature 
• Add 25 µl of sample diluent to each well 
• There will be one blank,three negative control and one positive control.Add 100 
µl of sample diluent and 50 ml of conjugate to blank 
• Add 75 µl of control and test specimen to the respective wells. 
• Add 50 µl of conjugate to each well. 
• Cover the plate with black cover and incubate at 37⁰C for 60 mins. 
• Wash the plate with washing solution. 
• Add 50 µl of color reagent. 
• Cover the plate with black cover and incubate in the dark for 15 mins. 
• Add 100 µl of stopping buffer to each well 
• Read the absorbency at 450 nm. 
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Interpretation: 
Positive: Absorbency of the test serum is equal or greater than the cut-off value. 
Negative: Absorbency of the test serum is less than the cut-off value. 
 
 
Figure No.8. ERBA LISA HBsAg Kit. 
Detection of HBV DNA by Real-time PCR assay 
Hepatitis-B Real-time PCR assay 
Material & Methods: 
PureFast® Viral nucleic acid minispin purification kit, HELINI Hepatitis-C Real-
time PCR kit from HELINI Biomolecules, Chennai, India 
Probe Master Mix: 
It contains 1.5U of HotstartTaq DNA polymerase, 10X Taq reaction buffer, 
3.5mM MgCl2,1µl of 10mM dNTPs mix and PCR additives 
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Viral DNA Purification 
1. Centrifuge tube of 1.5ml receives 0.2ml of plasma. 
2. Viral lysis buffer of 200µl and 5µl of internal control template and 20µl of Proteinase 
K, Mixed well by inverting several times. 
3. Incubate at 56ºC for 15min. 
4. Added 300µl of Ethanol and mixed well. 
5. The entire sample is transferred to pureFast® spin column. 1 minute Centrifugation 
allowed for the sample. After discarding the flow place it back in the collection tube. 
6. PureFast® spin column is added with 500 µl of wash buffer 1. Discard the flow after 
30-60 second centrifugation. The same process is repeated.  
7. PureFast® spin columnis added with500µl Wash buffer-2 .Allow 30-60 second 
Centrifugation. 
8. Additional 1 min centrifugation is allowed to avoid residual ethanol. 
9. PureFast® spin column is transferred to 1.5 ml micro-centrifuge tube. 
10.  The center of PureFast® spin column membrane is added with 60µl of elution 
buffer. 
11. Incubate for 1 min at room temperature and centrifuge for 2 min. 
12. Discard the column and store the purified viral nucleic acid at -20°C. 
DETECTION PROTOCOL 
Components HBV 
Probe PCR Master Mix 10 µl 
Hepatitis B Primer Probe Mix 2.5 µl 
Internal Control Primer Probe Mix 2.5 µl 
Purified Viral DNA 10 µl 
Total Volume 25 µl 
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Centrifuge PCR vials briefly before placing into thermal cycler 
Negative Control setup 
Add 10µl of nuclease free water instead of Purified DNA sample. 
Positive Control setup 
Add 10µl of Quantitative Positive control added 
 
Step Time Temperature 
Taq enzyme activation 15 min 95⁰ C 
 
 45 cycles 
Denaturation 20 sec 95⁰ C 
Annealing/Data Collection 20 sec 56⁰ C 
Extension 20 sec 72⁰ C 
 
 Data collection for HBV, FAM channel is used and for internal control, HEX 
channel is used. 
Hepatitis B virus Genotyping 
Material & Methods: 
PCR Master Mix, Purefast Viral DNA purification kit, , Agarose gel 
electrophoresis consumables and HELINI HBV Genotyping PCR kit are from HELINI 
Biomolecules, Chennai, Tamil Nadu 
 
Master Mix (2X) : 
10X Taq reaction buffer,2U of Taq DNA polymerase, 2mM MgCl2, 1µl of 
10mM dNTPs mix and PCR additives. 
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Agarose Gel Electrophoresis:- 
50X TAE buffer, Agarose, 6X gel loading buffer and Ethidium bromide are from 
HELINI Biomolecules, Chennai, Tamil Nadu. 
 
HBV Genotypes – PCR Products 
Set-1 
HBV-A – 514bp 
HBV-B – 368bp 
HBV-C – 607bp 
HBV-F – 217bp 
Set-2 
HBV-D – 756bp 
HBV-E – 588bp 
HBV-F – 217bp 
HBV-G – 366bp 
 
Procedure: 
1.  Plasma (200µl) is added into 1.5ml tube. 
2.  Lysed buffer(200µl) is added and mixed by vortex. 
3. 20 of Proteinase K added 
4. Mixed and incubated at 56°C for 15min. 
5. 300ul of ethanol mixed. 
6. PureFast spin column is added with whole lysate into and allowed centrifugation for 1 
minute at 10000rpm. 
7. Discard flow through and added 500µl of Wash Buffer-1 and Centrifuge at 10000rpm 
   1 min. 
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8. Discard flow through and added 500µl of Wash Buffer-2 and centrifuged at 
    10000rpm for 1min. Repeated wash one more time. 
9. Discarded flow through and Centrifuged column for additional 2 minute to remove 
    any residual ethanol. 
10. Eluted DNA by adding 100µl of Elution Buffer and Centrifuged for 1min. 
11. Quality and Quantity is checked using Nano-spectrophotometer 
 
HBV Genotyping Protocol 
Components Genotype 
set-I 
Genotype 
set-I 
RedDye PCR Master Mix 10µl 10µl 
Genotype Set -1 Primer Mix 10µl ---- 
Genotype Set-II Primer Mix ---- 10µl 
Purified Viral DNA 5µl 5µl 
Total reaction volume 25µl 25µl 
 
Centrifuge PCR vials briefly before placing into thermal cycler. 
AMPLIFICATION PROTOCOL 
 Step Time Temperature 
 
Taq enzyme 
activation 5 min 95⁰ C 
 
       38cycles 
Denaturation 30 sec 95⁰ C 
Annealing 30 sec 58⁰ C 
Extension 1 min 72⁰ C 
 
Final extension 5 min 72⁰ C 
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Expected PCR Product size 
HBV Genotype Sets –I 
HBV Genotype- C – 607bp 
HBV Genotype-A – 514bp 
HBV Genotype-B – 368bp 
HBV Genotype-F – 217bp 
HBV Genotype sets - II 
HBV Genotype- D – 756bp 
HBV Genotype-E – 588bp 
HBV Genotype-G – 366bp 
HBV Genotype-H – 217bp 
Gel electrophoresis: 
Prepare 2.5% agarose gel as per standard procedure. Load entire PCR amplified 
product along with 10µl of 100bp DNA Ladder. PCR product can be 
Directly loaded and not necessary to mix gel loading dye. Run electrophoresis and 
visualise in UV Transilluminator. 
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DETECTION OF ANTI-HCV BY ELISA 
PRINCIPLE: 
 The ErbaSure HCV Gen3 is a third generation indirect solid phase enzyme 
immunosorbent assay used for the qualitative determination of antibodies to Hepatitis C 
virus in human serum. Themicroplate wells are coated with recombinant and synthetic 
antigens of HCV.The test specimen is incubated with sample diluent in the coated 
microwells. If the anti-HCV antibodies are present in the specimen, it will bind with the 
coated antigen. Thewells are washed to remove the unbound antibodies. The bounded 
anti HCV antibodies are detected by the addition of peroxidase conjugate. Next add the 
substrate to detect the presence of bound conjugate.it gives blue color. Finally enzyme 
substrate reaction is stooped by adding stop solution and the cut off value is calculated. 
PROCEDURE: 
• Add 200 µl of sample diluent to each well 
• Each time there will be three negative controls and one positive controls 
• Add 10 µl of controls and specimen to respective wells. 
• Incubate at 37 ⁰C for 60 minutes. 
• Wash all the wells with washing solution for five times per well 
• Add 200µl of substrate solution to each well 
• Incubate in the dark at room temperature for 30 mins 
• Add 50 µl of stop solution into each well  
• Read the absorbance at 450nm. 
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Interpretation: 
Positive:Absorbance greater than or equal to the cut off value 
Negative: Absorbance less than the cut off value. 
 
 
Figure No.9.ERBA SURE HCV Kit 
DETECTION OF HCV RNA BY Real-time PCR assay 
                   Hepatitis-C Real-time PCR assay 
Material & Methods: 
Total RNA purification kit (PureFast® Total RNA Minispin purification kit), HELINI 
Hepatitis-C Real-time PCR kit from HELINI Biomolecules, Chennai, India. 
Single step RT-PCR Probe Master Mix: 
It contains 1.5U of HotstartTaqDNA ,10X Taq reaction buffer,3.5mM MgCl2, MULV-
Reverse transcriptase, RNase Inhibitors, polymerase, 1µl of 10mM dNTPs mix and PCR 
additives. 
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RNA Purification Process 
1. To1.5ml centrifuge tube 0.2ml of plasma is transferred. 
2.5µl of internal control template, Added 200µl of Viral lysis buffer, and 20µl of     
Proteinase K, Mixed by inverting several times. 
3. Incubate at 56ºC for 15min. 
4. Added 300µl of Ethanol and mixed well. 
5. Transferred entire sample into the PureFast® spin column. Centrifuged for 1 min. 
Discard the flow-through and place the column back into the same collection tube. 
6. Added 500µl Wash buffer-1 to the PureFast® spin column. Centrifuge for 30-60 
seconds and discard the flow-through. Place the column back into the same collection 
tube. 
7. Added 500µl Wash buffer-2 to the PureFast® spin column. Centrifuge for 30-60 
seconds and discard the flow-through. Place the column back into the same collection 
tube. 
8. Discard the flow-through and centrifuge for an additional 1 min. This step is essential    
to avoid residual ethanol. 
9. Transferred the PureFast® spin column into a fresh 1.5 ml micro-centrifuge tube. 
10. Added 60µl of Elution Buffer to the center of PureFast® spin column membrane. 
11. Incubate for 1 min at room temperature and centrifuge for 2 min. 
12. Discard the column and store the purified viral nucleic acid at -20°C 
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DETECTION PROTOCOL 
COMPONENTS HCV 
Probe PCR Master Mix 10 µl 
Hepatitis-C Primer Probe Mix 2.5 µl 
Internal control Primer Probe Mix 2.5 µl 
Purified RNA 10 µl 
Total volume 25 µl 
 
Centrifuge PCR vials briefly before placing into thermal cycler. 
 
Negative Control setup 
Add 10µl of nuclease free water instead of Purified RNA sample. 
Positive Control setup 
Add 10µl of Quantitative Positive control added 
THERMAL CYCLER 
 Step Time Temp 
 Reverse Transcriptase 30MIN 42⁰ C 
Taq enzyme activation 15MIN 95⁰ C 
 
50Cycles 
Denaturation 20SEC 95⁰ C 
Annealing/Data collection 20SEC 56⁰ C 
Extension 20SEC 72⁰ C 
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HCV GENOTYPING 
Materials 
Purified HCV RNA, HELINI HCV genotyping Real-time PCR kit and Agilent Real-time 
PCR machine – MX3000P 
Methods 
For each sample, three tubes of reactions, first tube contains a Primer Probe for HCV 
Genotype 1 and 2, Second tube contains a Primer Probe HCV genotype 3 & 4 and third 
tube contains a primer probe for genotype 5 & 6. 
Genotype 1, 3 and 5 – Probes are labelled with FAM dye 
Genotype 2, 4 and 6 – Probes are labelled with HEX dye 
Real-time PCR setup 
 
Components Genotype 
1 & 2 
Genotype 
3 & 4 
Genotype 
5 & 6 
Probe PCR Master 
Mix 
10 µl 10 µl 10 µl 
Primer Probe Mix 5 µl 5 µl 5 µl 
Purified RNA 
sample 
10 µl 10 µl 10 µl 
Total reaction 
volume 
25 µl 25 µl 25 µl 
 
Thermal Profile 
 Step Time Temp 
 
 
Reverse transcription 13min 42⁰C 
Taq enzyme activation 15min 95⁰C 
40 Cycles denaturation 20sec 95⁰C 
Annealing/data collection 20sec 56⁰C 
Extension 20sec 72⁰C 
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STATISTICAL ANALYSIS 
 
All statistical analysis were performed using SPSS version 22 with p < 0.05 
accepted as statistically significant. The Chi-square test was used for categorical 
variables. 
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6.RESULTS 
During the study period from October 2014-july 2015 a total of 194 samples were 
collected and tested for HBsAg and anti-HCV Ab at central service diagnostic 
laboratory,Departmentment of microbiology, Tertiary care hospital,Thanjavur medical 
college,Thanjavur. 
Table 4: Age Wise Distribution 
AGE(years) NO.OF CASES PERCENTAGE(%) 
<20 years 13 6.7% 
21-30 years 45 23.2% 
31-40 years 48 24.7% 
41-50 years 35 18.0% 
51-60 years 36 18.6% 
61-70 years 15 7.7% 
71 &ABOVE 2 1.0% 
TOTAL 194 100% 
 
Table 4 shows the age wise distribution of cases. A total of  194 blood samples were 
tested for both HBsAg and anti-HCV Ab.Higher number of cases were among the age 
group from 21-30 years 45(23.2%),followed by 31-40 years48(24.7%),51-60 years 
36(18.6%) .Lesser no of cases were among the age group <20 years 13(6.7%), followed 
by61-70 years15(7.7%) and above 71 years2(1.0%) 
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Figure :10.Age Distribution 
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TABLE 5: SEX WISE DISTRIBUTION 
SEX NO. OF CASES PERCENTAGE (%) 
MALE 143 73.7% 
FEMALE 51 26.3% 
TOTAL 194 100% 
 
Table 5 shows the sex wise distribution of cases.Out of 194 cases, 143(73.7%) were 
males and 51(26.3%) were females.Numbers of cases were higher among males than 
Females. 
Figure:11. Sex Distribution 
SEX DISTRIBUTION
51
143
MALE
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Table 6: Age And Sex Wise Distribution 
AGE(yrs) MALE % FEMALE % TOTAL.NO.CASES TOTAL % 
<20 7 4.9 6 11.8 13 6.7 
21-30 29 20.3 16 31.4 45 23.2 
31-40 42 29.4 6 11.8 48 24.7 
41-50 26 18.2 9 17.6 35 18.0 
51-60 28 19.6 8 15.7 36 18.6 
61-70 10 7.0 5 9.8 15 7.7 
71&above 1 7 1 2.0 2 1.0 
 
Table 6 shows the age and sex wise distribution of cases.Higher number of males were 
among the age group of 31-40 years 42(29.4%),followed by 21-30 years 29 (20.3%),51-
60 years 28(19.6%),41-50 years 26(18.2%).Lesser number of males were among the age 
group <20 years7(4.9%%)and 61-70 years 10(7%).similarly higher number of females 
were among the age group were among the age group 21-30 years 16(31.4%), followed 
by other age groups. 
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Figure 12: Age and Sex Wise Distribution 
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Table7: HbsAgPositiveCasesby Elisa 
RESULT n=194 PERCENTAGE (%) 
POSITIVE 8 4.1% 
NEGATIVE 186 95.9% 
 
Table 7 shows HBsAg positive cases by Elisa. Out of 194 samples 8(4.1%) cases were 
positive by Elisa. Remaining 186(95.9%) samples were negative by Elisa. 
 
Figure12: HBsAgPositive Cases by Elisa 
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Figure14:Elisa Microplate  
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Table 8: Age Wise HBsAgPositive Cases 
 
 
TABLE 8 shows the age distribution of HBsAg positive cases.It shows that 
higher numbers of positive cases were among the age group below20 years, 2 (15.38%), 
followed by the age group above 21years 3(6.6%).Least no of positive cases were among 
the age above 31 years 1(2.08%).No positive cases were among the age group above 50 
years. Significance was calculated with chisquare test .p value was 0.244 > 0.05. 
 
 
 
 
AGE NO.OF CASES TESTED POSITIVE % 
<20 13 2 15.38% 
21-30 45 3 6.6% 
31-40 48 1 2.08% 
41-50 35 2 5.71% 
51-60 36 0 0% 
61-70 15 0 0% 
71&above 2 0 0% 
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Figure15: Age Wise HBsAg Positive Cases 
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Table 9: Sex Wise HBsAg Positive Cases 
SEX NO.OF CASES 
TESTED 
HBSAG 
POSITIVE 
PERCENTAGE 
(%) 
MALE 143 6 4.19% 
FEMALE 51 2 3.92% 
 
TABLE 9 shows the gender wise HBsAg positive cases.Out of 143 cases 6 were 
positive among males and out of 51 cases 2 were positive among females.It shows that 
the highest prevalence were among males 6(4.19%) compared to females 2 
(3.92%).Significance was calculated with chisquare test .p value was 0.933 > 0.05. 
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Figure 16: Sex Wise HBSAgPositive Cases 
SEX WISE PREVALENCE
6
2
MALE
FEMALE
 
 
 
 
 
 
 
 
 
 
68 
 
 
 
Table10: Age and SexwiseHBsAgPositive Cases 
AGE(yrs) 
NO.OF 
MALES 
TESTED 
n=143 
POSITIVE % 
NO.OF 
FEMALES 
TESTED 
n=51 
POSITIVE % TOTAL (%) 
<20 7 2 28.57% 6 0 0% 2(28.57%) 
21-30 29 1 3.44% 16 2 12.5% 3(15.94%) 
31-40 42 1 2.38% 6 0 0% 1(2.38%) 
41-50 26 2 7.69% 9 0 0% 2(7.69%) 
51-60 28 0 0% 8 0 0% 0(0%) 
61-70 10 0 0% 5 0 0% 0(0%) 
71&above 1 0 0% 1 0 0% 0(0%) 
TOTAL 143 6 4.1% 51 2 3.92% 8(4.1%) 
 
TABLE 10: shows the age and sex distribution of the total number of cases with HBsAg 
seroprevalence.The seroprevalence of HBsAg was found to be 4.1%.The seroprevalence 
of HBsAg among males were found to be 4.1% and females were 3.92 %.The highest 
seroprevalence of HBsAg was found in males below the age of 20 years(28.57%) 
followed by the age group above 40(7.69%) 
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Figure17: Age and Sex Wise HBSAgPositive Cases 
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Result of Hepatitis B Real-time PCR assay: 
Hepatitis B Real-time PCR assay was done for 13 samples out of 194 samples. 
Out of 13 samples, 8 samples were positive for HBsAg done by ELISA 
test.Remaining 5 samples were negative by ELISA test.  
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Table 11: Hepatitis B Real Time PCR Assay 
METHOD POSITIVE NEGATIVE TOTAL 
ELISA 8 5 13 
Real-time PCR 1 12 13 
 
 Table 11 shows that out of 13 samples,1sample (8%) was positive for HBV 
DNA and 12 samples were negative (92%) for HBV DNA by Real- time 
PCRassay. Out of 13 samples, 1(8%) sample were positive both by ELISA and 
Real- time PCR assay and5 (38%) samples were negative by both ELISA 
andReal time PCR assay.Remaining 7(54%) samples initially positive for 
Hepatitis B surface antigen by ELISA,were negative by Real- time PCR for HBV 
DNA analysis. 
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Figure18:Real time PCR for HBV. 
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Figure19: PLATE SET UP. 
 
Figure 19 shows plate set up of 13 samples, one standard and one negative 
control. 
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Figure20:    Amplification  plots 
 
Figure 20: shows the Amplification plots for samples and standards. Cycle 
threshold for standard was 30.06 and for sample were 37.98.  
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Quantitative analysis by Real time PCR 
QS3-well-G8 = 15000copies/ml = 2884IU/ml 
Sample-well-A8-300copies/ml = 57IU/ml 
   Viral load is determined by total number of viral copies per ml of sample. Viral 
load depends upon stage of illness.Since it is a real time PCR quantification of the viral 
load can also be measured.  For the one positive sample, the viral load is 300 copies/ml 
which is equal to 57IU/ml. 
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Figure 21: Result of Molecular characterization by Genotyping 
 
 
Figure 21: One positive sample which was positive for HBV DNA by Real-time 
PCR assay was further processed for Molecular characterization by Genotyping. 
Conventional Polymerase Chain reaction was done for Genotyping. Genotype C 
was detected for the positive sample. 
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Table 12: Anti-HCVAbPositive by Elisa  
RESULT n=194 PERCENTAGE (%) 
Positive 5 2.6% 
Negative 189 97.4% 
 
Table12 shows the total number of anti- HCV Ab positive and anti HCV  Ab negative 
cases.Out of 194 samples tested, only 5(2.6%) out of 194 showed higher OD value in 
anti HCV Ab Elisa test.Remaining 189 (97.4%) showed negative results. 
Figure 22: Anti-HCVAb Positive by 
Elisa
Anti-HCV positive 
2.60%
97.40%
Positive 
Negative
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Table 13: Age Wise Anti-HCVAbPositive  
AGE(years) NO.OF CASES TESTED POSITIVE PERCENTAGE(%) 
<20 13 0 0% 
21-30 45 2 4.44% 
31-40 48 0 0% 
41-50 35 1 2.85% 
51-60 36 0 0% 
61-70 15 2 13.33% 
71&above 2 0 0% 
 
TABLE 13 shows the agewise distribution of anti HCV Ab positive cases. It shows that 
higher numbers of positive cases were among the age group above 30-40 years (4.44%), 
and above 60 years(13.33%).Least no of positive cases were among the age above 40 
years(2.85%).Significance was calculated with chisquare test .p value was 0.118 > 0.05. 
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Figure 23:Age Wise Anti HCV AbPositive Cases 
 
79 
 
 
Table 14: Sex Wise Anti-HCVPositive  
SEX NO.OF CASES TESTED POSITIVE PERCENTAGE (%) 
MALE 143 4 2.79% 
FEMALE 51 1 1.96% 
 
TABLE 14 shows the gender wise anti HCV Ab positive cases.It shows that highest 
prevalence were among males 4(2.79%) compared to females 1(1.96%).Significance was 
calculated with chisquare test .p value was 0.746 > 0.05. 
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Figure 24 :Sex Wise Anti-HCVAb Positive. 
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Table15: Age and Sex Wise Anti-HCVAbSeropositivity 
AGE(yrs) MALE 
n=143 
POSITIVE % FEMALE 
n=51 
POSITIVE % TOTAL 
POSITIVE 
(%) 
<20 7 0 0% 6 0 0% 0(0%) 
21-30 29 1 3.44% 16 1 6.25% 2(9.69%) 
31-40 42 0 0% 6 0 0% 0(0%) 
41-50 26 1 3.84% 9 0 0% 1(3.84%) 
51-60 28 0 0% 8 0 0% 0(0%) 
61-70 10 2 20% 5 0 0% 2(20%) 
70&above 1 0 0% 1 0 0% 0(0%) 
TOTAL 143 4 2.79% 51 1 1.96 5(2.6%) 
 
TABLE 15 shows the age and sexwise distribution of the total number of cases with anti-
HCVAbseroprevalence.The seroprevalence of anti –HCV Ab was found to be 2.6%.The 
seroprevalence of anti-HCV Ab among males were 2.79% and females were 1.96%.The 
highest seroprevalence of anti HCV Ab was found in males above the age of 61 years.  
82 
 
 
Figure 25: Age and Sex Wise Anti- HCVAbSeropositivity 
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Table 16: HBsAg and anti-HCV seroprevalence 
AGE (YEARS) NO.OF CASES HBsAgPOSITIVE(%) Anti-HCV 
POSITIVE(%) 
<20 13 2(15.38%) 0(0%) 
21-30 45 3(6.6%) 2(4.44%) 
31-40 48 1(2.08%) 0(0%) 
41-50 35 2(5.71%) 1(2.85%) 
51-60 36 0(0%) 0(0%) 
61-70 15 0(0%) 2(13.33%) 
71 &above 2 0(0%) 0(0%) 
TOTAL 194 8(4.1%) 5(2.6%) 
 
Table 16 shows the seroprevalence for both HBsAg and anti-HCV.Both HBsAg and anti-
HCV shows different seroprevalence among different age groups.In this study co-
infection of HBsAg and anti-HCV were not present. 
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Figure 26: HBsAg and anti-HCV seroprevalence 
 
HCV RNA DETECTION BY Real-time PCR 
Result of Hepatitis C Real-time PCR assay: 
Hepatitis C Real-time PCR assay was done for 8 samples, including positive & 
negative samples by ELISA from 194 study groups. 
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TABLE  17: Results of Real-time PCR 
   
METHOD POSITIVE NEGATIVE TOTAL 
ELISA 5 3 8 
Real-time PCR 3 5 8 
 
Out of 8 samples 3sample(38%) were positive for HCV RNA and 5 samples were 
negative(62%) for HCV RNA by Real- time PCR assay.Out of 8 samples 3(38%) sample 
were positive both by ELISA and Real- time PCR assay and 3 (38%) samples were 
negative by both ELISA and Real time PCR assay.Two(24%) samples which 
wereinitially positive for anti-HCV antibodies by ELISA were negative by Real-time 
PCR for HCV RNA analysis. 
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Figure 27:Real time PCR assay for HCV. 
 
  
  
 
 
 
 
 
 
 
 
87 
 
 
 
Figure 28:Amplification plots for HCV RNA 
 
Figure 28 shows amplication plots of RT PCR  for 8 samples and one standard .Cycle 
threshold for standard was 26.75, and for 3 samples were 29.58, 31.90, and 33.24 
respectively. 
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Quantitative analysis by Real time PCR 
HCV = 2.7copies = 1IU/ml 
NPC-well-G2 = 5000copies 
Sample-1-wellB2-123000copies/ml = 4x104 IU/ml 
Sample-2-wellC2-6400copies/ml = 1700IU/ml 
Sample-4-WellE2-11000copies/ml = 1.103 IU/ml 
Viral load is determined by total number of viral copies per ml of sample. Viral load 
depends upon the stage of illness. Since it is a real time PCR quantification of the viral 
load can also be measured. Sample 1 shows high viral load and sample 2 and 4 shows 
less viral load 
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Result of Molecular characterization by HCV Genotyping: 
 
Three positive samples which were positive for HCV RNAby Real-time PCR 
assay was further processed for Molecular characterization by Genotyping. Real-
time PCR was done for Genotyping. Genotype 1 was detected in sample 1 and 
genotype 3 was found in sample 3 and 4. 
FIGURE 29:HCV Genotyping 
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FIGURE 30:Amplification plot HCV Genotyping 
 
 
Figure 30 shows amplification plot of RT PCR genotyping of HCV. Cycle threshold for 
3 samples were 16.58,26.96&27.89 respectively. And detected asSample-1  belongsto 
HCV genotype – 1,Samples 3 &4 belongs to HCV genotype – 3. 
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Interpretation 
Sample-1 = HCV genotype - 1 detected in FAM channel 
Samples 3 &4 are HCV genotype - 3 detected in FAM channel 
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7.DISCUSSION 
Hepatitis B and C infections are a serious global and public health problem. Both HBV 
and HCV infections are transmitted mainly by blood and blood products. Worldwide two 
billion people are infected with HBV,and 350 million are chronic carriers. Based on the 
prevalence of HBV infections, it is classified into high (>8%), intermediate (2-7%) and 
low prevalence (<2%).72WHO recommended the universal immunization for hepatitis B 
and this reduces the hepatitis b carrier state.73HCV cause asymptomatic infection to 
chronic infection.It is one of the major causes of liver cirrhosis and hepatocellular 
carcinoma. WHO estimates that there are 180 million people affected worldwide. 
According toWHO global prevalence of HCV is 3%.The seroprevalence of HCV among 
general population in India is1.8%.74Seroprevalence study is important to assess the 
magnitude and disease transmission in the community. The present study has been taken 
to assess the seroprevalence of HBsAg and antibodies to HCV in both the sexes and 
different age groups in patients attending tertiary care hospital. 
Prevalence of Hepatitis B: 
          In this study the prevalence of hepatitis b was 4.6%. This value almost rationale 
with the prevalence rates of hepatitis b infections in developing countries. 
This prevalence rate is similar to prevalence rate 4.6% of the study by 
SameenAfzalJunejo et al during 2009 at Pakistan.75 
In another study Noorali et al states that Seroprevalence of hepatitis b is 4.5%.76 
In 2008, Hakim et al states that seroprevalence of hepatitis b is 4.5%.77 
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Age Prevalence for Hepatitis B: 
In table 8, the highest prevalence for the age group was seen among 20-50 
years.No prevalence rates for the age group beyond 50 years. The highest prevalence rate 
was seen among the age group 20-50 showing similarity with the study conducted by 
Khakhkharvipul M et al,78Sangramsinghpatel et al.79There was no significant difference 
between the age groups in this present study. 
Sex Prevalence for Hepatitis B: 
In the present study, Out of 194 cases, 143 were males and 51 were females. 
Male gender showed higher positive results for HBsAg compared to females. There was 
no significant difference between the male and the female.Patil SS et al80 and Nafees et 
al81 stated that the highest prevalence was seen among males than females. 
HBV DNA detection by Real-time PCR: 
Out of eight samples, 1 sample was positive both by ELISA and Real-time PCR. 
Seven samples which were positive by ELISA, also negative by Real-time PCR. The 
reason may be due to either inactive HBV carrier state or resolved infection with HBV 
immunity. In inactive HBV carrier state HBsAg will be positive but HBV DNA may or 
may not be positive. In resolved infection only the HBsAg will be present but HBV will 
be completely absent.82 
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Quantitative analysis by Real time PCR: 
Viral load is determined by total number of viral copies per ml of sample. Viral 
load depends upon stage of illness. Since it is a real time PCR quantification of the viral 
load can also be measured. The viral load for the one positive sample is 300 copies/ml 
that is equal to 57 IU/ml. 
This result indicates that the patient might be in Inactive HBsAg carrier 
state.The Inactive HBsAg carrier state is defined as absence of HBeAg,presence of 
HBeAb,normal serum ALT levels and HBV DNA <2000 IU/ml. 
Gupta et al stated that samples with >2000 IU/ml of HBV DNA is considered as 
high HBV DNA.4 
According to Changotra et al,viral load plays an important role in defining the 
state of infection,implementing drug regimen and to monitor antiviral treatment.83 
 Molecular characterization by Genotyping (HBV): 
One positive sample which was positive for HBV DNA by Real-time PCR assay 
was further processed for Molecular characterization by Genotyping.Conventional 
Polymerase Chain reaction was done for Genotyping. Genotype C was detected for the 
positive sample. 
ToumyGuettouche states that determination of genotype is important for the 
patients with chronic hepatitis. It plays a vital role in duration of anti-viral therapy and 
predicting response to therapy.84 
Vivekanandan et al states that Genotype C is associated with severe liver disease 
and lesser response to INF –alpha when compared with Genotype B. 
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Prevalence of Hepatitis C: 
Table 12 shows that the prevalence of hepatitis C in this present study was 2.6%. 
This seroprevalence is almost similar to the study conducted at Andhra Pradesh 
which was 2.02%. 
In India seroprevalence of HCV varies from 1.5% from Cuttack to 4.8% from 
Pondicherry. 
 Study conducted by Sharma et al in 2007 from Jaipur stated that Seroprevalence 
for Hepatitis C as 1.7% .This study does not support my present study.85 
Age Prevalence for Hepatitis C: 
Table 13 shows that the age prevalence was high among the age groups 30-40 
years(4.4%) and >61 years(13.13%).It is almost similar to the study conducted by 
Smitasood et al in 2015. Ramarokoto et al in their study stated that prevalence did not 
differ significantly based on sex but it increased with age.86 
Sex Prevalence for Hepatitis C: 
Table 14 shows that seroprevalence of HCV was higher among males than 
females.There was no statistically significant difference in the prevalence rates for males 
and females. Bhattacharya et al87in their study stated that seroprevalence was higher 
among males than females.Another study reported by NafeesMet,86SayeedulHasanArif et 
al,2ManjunathPsalmani stated that the seroprevalence was high among males than 
females.80 
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Hepatitis C Real-time PCR Assay: 
  Out of 8 samples 3 sample(38%) were positive for HCV RNA and 5 samples 
were negative(62%) for HCV RNA by Real- time PCR assay.Out of 8  samples 3 (38%) 
sample were positive both by ELISA and Real- time PCR assay and 3 (38%) samples  
were negative by both ELISA and  real time PCR assay.  Two (24%) samples which 
were initially positive for anti-HCV antibodies by ELISA were negative by Real-time 
PCR for HCV RNA analysis. 
   Reddy et al states that antibody tests fails to detect HCV infected patients before 
seroconversion or during the window period. But the viral RNA can be detected in the 
serum. Window period for immunocompetant subjects may extend upto two months 
whereas for immunosuppressed individuals, it may extend upto 12 months. Direct 
detection of HCV RNA in the serum remains the gold standard test to diagnose HCV 
infection.93 
 Molecular characterization by Genotyping: 
  Three positive samples which were positive for HCV RNAby Real-time PCR 
assay was further processed for Molecular characterization by Genotyping. Real-time 
PCR was done for Genotyping. Genotype 1 was detected in sample 1 and genotype 3 
was found in sample 3 and 4. 
  In the present study Genotype 3 was present in two samples and Genotype 1 was 
present in one sample. 
  Chakravarti et al in their study states that genotype 3 is common in north India.11 
In another study conducted by Christdas et al states that genotype 3 is predominant in 
south India.10 
Saha et al in their states that Genotype 3(34.09%) is common followed by 
Genotype 1(7.95%).9 
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Limitations of the Study: 
In the present study some diagnostic tests for HBV were not performed such as 
 Serological marker such as anti-HBcIgM to rule acute infection. 
 Serological marker Anti-HBs which rule out infection due to natural cause or  by 
vaccination. 
Strength of the study: 
 Quantitative HBV DNA for 13 samples and HCV RNA for 8 samples were 
diagnosed by Real-time PCR assay. 
 Genotyping for both HBV and HCV was done to know about the Genotype 
circulating in Thanjavur district. 
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8.SUMMARY 
 
The study was conducted at Thanjavur Medical College Hospital;Thanjavur over 
a period of October 2014 to July 2015.The aim of the study is to determine 
theseroprevalence of hepatitis B surface antigen and antibodies to hepatitis C in patients 
attending tertiary care hospital and molecular characterization for both HBV and HCV. 
Serum samples were collected from 194 samples. All these samples were initially tested 
for hepatitis B surface antigen and antibodies to hepatitis C by Elisa. Molecular detection 
method was done for the positive samples by real time PCR assay. Serum samples were 
stored at -20 c until tested for molecular detection. Real time PCR was done for 13 
samples, including both positive and negative for HBsAg. Out of 13 samples, 8 samples 
were positive by Elisa. One sample was positive for HBV DNA by Real-time PCR assay 
and this one positive sample was further processed for HBV genotyping. Similarly Real- 
time PCR was done for 8 samples including both positive and negative for anti HCV Ab. 
Out of 8 samples, 5 samples were for anti HCV Elisa. Three samples were positive for 
HCV RNA by real time PCR assay.All the three samples were further processed for 
HCV genotyping.  
 Prevalence of hepatitis b virus was 4.1%. 
 High prevalence was seen in the age group 20-50 years. 
 High prevalence was seen among males (4.19%) than females(3.92%). 
 There was no significant difference between males and females. 
 Real –time PCR for HBV DNA was positive for one sample (8%) out of 8 
positive samples by Elisa. 
 Genotyping for the one positive sample was genotype C. 
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 Prevalence of Hepatitis C virus was 2.6%. 
 High prevalence was seen among males (2.79%) than females(1.96%). 
 There was no significant difference between males and females. 
 Real-time PCR for HCV RNA was positive for three samples (38%) out of total 8 
samples. 
 Genotyping for the positive samples showed that genotype 3 was detected in two 
samples and genotype 1 was detected in one sample. 
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9.CONCLUSION 
 
This study estimates the seroprevalence of Hepatitis B and Hepatitis C for both 
the sexes in patients attending tertiary care hospital. The seroprevalence of Hepatitis B 
was 4.1% and hepatitis c was 2.6%.The prevalence was high among males when 
compare to females for both hepatitis b and hepatitis C.Seroprevalence study estimates 
the magnitude and dynamics of disease transmission .Real –time PCR is the gold 
standard method, because it estimates the viral load and genotyping, because both viral 
load and genotyping plays an important role in treatment strategy. Moreover knowing 
about the genotypes in the community helps in the development of future vaccine. 
Further studies of genotype distribution will helps in the development, adaptation and 
prevention strategies. Early diagnosis prevents the disease progression and further 
complications.  
 
 
 
 
 
 
 
 
 
APPENDIX 1 
1. PREPARATION OF WASHING SOLUTION (HBsAg) 
    Dilute the washing solution (1+9) in distilled or deionized water.Washing 
solution is crystalised at cool storage condition.Use it after thawing at 37⁰C water 
bath.washing cycles should be six cycles with 0.35 ml of wash buffer per well. 
Soak time is 30 seconds. After washing ,invert the plate and tap it on absorbent pad 
to remove the remaining washing solution. 
2. PREPARATION OF WASHING SOLUTION (HCV) 
        Dilute the washing solution (1:20) with distilled water or de-ionized 
water.Washing solution is crystalised at cool temperature.Use it after thawing at 
37⁰Cwaterbath. 
3. PREPARATION OF CONJUGATE: 
Dilute the conjugate (1:101) dilution with conjugate diluent 10 minutes 
before use. 
 
 
 
 
 
Table 1 
strips 1 2 4 6 8 10 12 
Conjugate diluent(ml) 2 4 8 12 16 20 24 
Concentratedconjugate(µl) 20 40 80 120 160 200 240 
 
PREPARATION OF SUBSTRATE 
Dilute the substrate (1:101) with substrate buffer 5 to 10 mins before use. 
Table 2 
strips 1 2 4 6 8 10 12 
Substrate 
buffer(ml) 
2 4 8 12 16 20 24 
Concentrated 
substrate(µl) 
20 40 80 120 160 200 240 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
PROFORMA 
 
NAME:        SERIAL NO: 
AGE:                   LAB NO: 
SEX:         OP/IP NO: 
Address:       Date of sample collection 
Occupation: 
Income: 
CHEIFS COMPLAINTS: 
1. FEVER 
2. MALAISE 
3. VOMITING 
4. ABDOMINAL PAIN 
5. LOSS OF APPETITE 
 
PAST HISTORY: 
1. JAUNDICE 
2. BLOOD TRANSFUSION 
3. SMOKING 
4. ALCOHOLIC 
 
PERSONNEL HISTORY 
 
FAMILY HISTORY: 
 
 
CLINICAL DIAGNOSIS: 
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S.NO AGE SEX HBsAg Anti HCV
1 30 FEMALE POSITIVE NEGATIVE
2 28 MALE NEGATIVE NEGATIVE
3 22 FEMALE NEGATIVE POSITIVE
4 34 MALE NEGATIVE NEGATIVE
5 65 FEMALE NEGATIVE NEGATIVE
6 27 MALE NEGATIVE NEGATIVE
7 27 FEMALE NEGATIVE NEGATIVE
8 45 MALE POSITIVE NEGATIVE
9 50 MALE NEGATIVE NEGATIVE
10 53 MALE NEGATIVE NEGATIVE
11 51 MALE NEGATIVE NEGATIVE
12 70 FEMALE NEGATIVE NEGATIVE
13 70 FEMALE NEGATIVE NEGATIVE
14 48 MALE NEGATIVE NEGATIVE
15 40 MALE NEGATIVE NEGATIVE
16 34 MALE NEGATIVE NEGATIVE
17 40 MALE NEGATIVE NEGATIVE
18 30 MALE NEGATIVE NEGATIVE
19 37 MALE NEGATIVE NEGATIVE
20 42 MALE POSITIVE NEGATIVE
21 20 MALE POSITIVE NEGATIVE
22 55 FEMALE NEGATIVE NEGATIVE
23 60 FEMALE NEGATIVE NEGATIVE
24 40 MALE NEGATIVE NEGATIVE
25 53 MALE NEGATIVE NEGATIVE
26 16 FEMALE NEGATIVE NEGATIVE
27 35 MALE NEGATIVE NEGATIVE
28 27 MALE NEGATIVE NEGATIVE
29 30 MALE NEGATIVE NEGATIVE
30 50 MALE NEGATIVE NEGATIVE
31 44 MALE NEGATIVE POSITIVE
32 38 MALE NEGATIVE NEGATIVE
33 40 MALE NEGATIVE NEGATIVE
34 30 MALE POSITIVE NEGATIVE
35 35 MALE NEGATIVE NEGATIVE
36 18 FEMALE NEGATIVE NEGATIVE
37 57 MALE NEGATIVE NEGATIVE
38 60 MALE NEGATIVE NEGATIVE
39 19 FEMALE NEGATIVE NEGATIVE
40 47 MALE NEGATIVE NEGATIVE
41 27 MALE NEGATIVE NEGATIVE
42 60 MALE NEGATIVE NEGATIVE
43 48 MALE NEGATIVE NEGATIVE
44 55 MALE NEGATIVE NEGATIVE
45 26 MALE NEGATIVE NEGATIVE
46 17 MALE NEGATIVE NEGATIVE
47 50 MALE NEGATIVE NEGATIVE
48 55 FEMALE NEGATIVE NEGATIVE
49 24 FEMALE POSITIVE NEGATIVE
50 35 MALE NEGATIVE NEGATIVE
51 25 MALE NEGATIVE NEGATIVE
52 54 MALE NEGATIVE NEGATIVE
53 35 FEMALE NEGATIVE NEGATIVE
54 24 FEMALE NEGATIVE NEGATIVE
55 26 MALE NEGATIVE NEGATIVE
56 65 FEMALE NEGATIVE NEGATIVE
57 18 FEMALE NEGATIVE NEGATIVE
58 48 MALE NEGATIVE NEGATIVE
59 54 MALE NEGATIVE NEGATIVE
60 28 MALE NEGATIVE NEGATIVE
61 32 MALE NEGATIVE NEGATIVE
62 23 MALE NEGATIVE POSITIVE
63 36 FEMALE NEGATIVE NEGATIVE
64 48 FEMALE NEGATIVE NEGATIVE
65 40 MALE NEGATIVE NEGATIVE
66 30 FEMALE NEGATIVE NEGATIVE
67 52 MALE NEGATIVE NEGATIVE
68 38 FEMALE NEGATIVE NEGATIVE
69 56 MALE NEGATIVE NEGATIVE
70 55 FEMALE NEGATIVE NEGATIVE
71 60 MALE NEGATIVE NEGATIVE
72 35 MALE NEGATIVE NEGATIVE
73 40 MALE NEGATIVE NEGATIVE
74 60 MALE NEGATIVE NEGATIVE
75 45 FEMALE NEGATIVE NEGATIVE
76 70 FEMALE NEGATIVE NEGATIVE
77 65 MALE NEGATIVE POSITIVE
78 50 MALE NEGATIVE NEGATIVE
79 33 MALE NEGATIVE NEGATIVE
80 23 FEMALE NEGATIVE NEGATIVE
81 26 MALE NEGATIVE NEGATIVE
82 34 MALE NEGATIVE NEGATIVE
83 35 MALE NEGATIVE NEGATIVE
84 45 MALE NEGATIVE NEGATIVE
85 22 MALE NEGATIVE NEGATIVE
86 26 MALE NEGATIVE NEGATIVE
87 27 MALE NEGATIVE NEGATIVE
88 13 FEMALE NEGATIVE NEGATIVE
89 36 MALE NEGATIVE NEGATIVE
90 67 MALE NEGATIVE NEGATIVE
91 57 MALE NEGATIVE NEGATIVE
92 68 MALE NEGATIVE NEGATIVE
93 48 FEMALE NEGATIVE NEGATIVE
94 40 MALE NEGATIVE NEGATIVE
95 39 MALE NEGATIVE NEGATIVE
96 47 MALE NEGATIVE NEGATIVE
97 44 MALE NEGATIVE NEGATIVE
98 29 MALE NEGATIVE NEGATIVE
99 32 MALE POSITIVE NEGATIVE
100 26 FEMALE NEGATIVE NEGATIVE
101 39 MALE NEGATIVE NEGATIVE
102 50 MALE NEGATIVE NEGATIVE
103 76 MALE NEGATIVE NEGATIVE
104 60 MALE NEGATIVE NEGATIVE
105 40 MALE NEGATIVE NEGATIVE
106 59 MALE NEGATIVE NEGATIVE
107 40 MALE NEGATIVE NEGATIVE
108 49 MALE NEGATIVE NEGATIVE
109 24 FEMALE NEGATIVE NEGATIVE
110 60 MALE NEGATIVE NEGATIVE
111 18 MALE NEGATIVE NEGATIVE
112 45 FEMALE NEGATIVE NEGATIVE
113 60 MALE NEGATIVE NEGATIVE
114 70 MALE NEGATIVE POSITIVE
115 18 MALE NEGATIVE NEGATIVE
116 27 MALE NEGATIVE NEGATIVE
117 70 MALE NEGATIVE NEGATIVE
118 44 MALE NEGATIVE NEGATIVE
119 41 MALE NEGATIVE NEGATIVE
120 52 MALE NEGATIVE NEGATIVE
121 30 FEMALE NEGATIVE NEGATIVE
122 55 MALE NEGATIVE NEGATIVE
123 65 MALE NEGATIVE NEGATIVE
124 28 MALE NEGATIVE NEGATIVE
125 45 MALE NEGATIVE NEGATIVE
126 28 MALE NEGATIVE NEGATIVE
127 50 MALE NEGATIVE NEGATIVE
128 26 FEMALE NEGATIVE NEGATIVE
129 35 MALE NEGATIVE NEGATIVE
130 60 MALE NEGATIVE NEGATIVE
131 38 FEMALE NEGATIVE NEGATIVE
132 55 MALE NEGATIVE NEGATIVE
133 25 FEMALE NEGATIVE NEGATIVE
134 72 FEMALE NEGATIVE NEGATIVE
135 44 FEMALE NEGATIVE NEGATIVE
136 61 MALE NEGATIVE NEGATIVE
137 33 MALE NEGATIVE NEGATIVE
138 48 FEMALE NEGATIVE NEGATIVE
139 37 MALE NEGATIVE NEGATIVE
140 39 MALE NEGATIVE NEGATIVE
141 22 MALE NEGATIVE NEGATIVE
142 18 MALE NEGATIVE NEGATIVE
143 55 FEMALE NEGATIVE NEGATIVE
144 48 FEMALE NEGATIVE NEGATIVE
145 23 MALE NEGATIVE NEGATIVE
146 32 FEMALE NEGATIVE NEGATIVE
147 39 MALE NEGATIVE NEGATIVE
148 23 MALE NEGATIVE NEGATIVE
149 60 FEMALE NEGATIVE NEGATIVE
150 60 MALE NEGATIVE NEGATIVE
151 60 MALE NEGATIVE NEGATIVE
152 52 MALE NEGATIVE NEGATIVE
153 25 FEMALE NEGATIVE NEGATIVE
154 40 FEMALE NEGATIVE NEGATIVE
155 45 FEMALE NEGATIVE NEGATIVE
156 45 MALE NEGATIVE NEGATIVE
157 40 MALE NEGATIVE NEGATIVE
158 60 MALE NEGATIVE NEGATIVE
159 50 MALE NEGATIVE NEGATIVE
160 30 FEMALE NEGATIVE NEGATIVE
161 38 MALE NEGATIVE NEGATIVE
162 60 MALE NEGATIVE NEGATIVE
163 40 MALE NEGATIVE NEGATIVE
164 28 MALE NEGATIVE NEGATIVE
165 24 MALE NEGATIVE NEGATIVE
166 40 MALE NEGATIVE NEGATIVE
167 35 MALE NEGATIVE NEGATIVE
168 48 MALE NEGATIVE NEGATIVE
169 26 MALE NEGATIVE NEGATIVE
170 31 MALE NEGATIVE NEGATIVE
171 47 MALE NEGATIVE NEGATIVE
172 29 FEMALE NEGATIVE NEGATIVE
173 65 MALE NEGATIVE NEGATIVE
174 19 MALE NEGATIVE NEGATIVE
175 65 MALE NEGATIVE NEGATIVE
176 18 FEMALE NEGATIVE NEGATIVE
177 36 MALE NEGATIVE NEGATIVE
178 40 MALE NEGATIVE NEGATIVE
179 55 MALE NEGATIVE NEGATIVE
180 55 FEMALE NEGATIVE NEGATIVE
181 63 MALE NEGATIVE NEGATIVE
182 25 MALE NEGATIVE NEGATIVE
183 30 FEMALE NEGATIVE NEGATIVE
184 27 MALE NEGATIVE NEGATIVE
185 43 FEMALE NEGATIVE NEGATIVE
186 50 MALE NEGATIVE NEGATIVE
187 31 MALE NEGATIVE NEGATIVE
188 35 MALE NEGATIVE NEGATIVE
189 31 MALE NEGATIVE NEGATIVE
190 55 FEMALE NEGATIVE NEGATIVE
191 40 MALE NEGATIVE NEGATIVE
192 18 MALE POSITIVE NEGATIVE
193 27 MALE NEGATIVE NEGATIVE
194 46 MALE NEGATIVE NEGATIVE
